CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy

Babafemi Taiwo; Peter W. Hunt; Rajesh T. Gandhi; Andrew Ellingson; Matthew McKenna; Jeffrey M. Jacobson; Barbara Gripshover; Ronald J. Bosch

doi:10.1097/QAI.0b013e3182895af4

CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy

Babafemi Taiwo^*, Peter W. Hunt, Rajesh T. Gandhi, Andrew Ellingson, Matthew McKenna, Jeffrey M. Jacobson, Barbara Gripshover, Ronald J. Bosch

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Transient low-level viremia (TLLV) of 50-400 HIV RNA copies per milliliter is common during antiretroviral therapy, but its pathogenesis, consequences, and optimal management are unclear. Heightened immune activation is associated with detrimental outcomes, including impaired CD4 T-cell reconstitution. Using CD38/HLA-DR expression on CD8 T cells measured in 2 large studies, we determined associations between TLLV and immune activation levels before, during, and after TLLV. We found that TLLV does not significantly change CD8 T-cell activation and that higher CD8 T-cell activation during viral suppression <50 copies per milliliter is associated with a modest increase in the risk of a subsequent TLLV.

Original language	English (US)
Pages (from-to)	101-104
Number of pages	4
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	63
Issue number	1
DOIs	https://doi.org/10.1097/QAI.0b013e3182895af4
State	Published - May 1 2013

Keywords

CD8
activation
blip
immune
low level
viremia

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAI.0b013e3182895af4

Cite this

@article{25ad295d2e0c4b88bf82b5d26ce652c0,

title = "CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy",

abstract = "Transient low-level viremia (TLLV) of 50-400 HIV RNA copies per milliliter is common during antiretroviral therapy, but its pathogenesis, consequences, and optimal management are unclear. Heightened immune activation is associated with detrimental outcomes, including impaired CD4 T-cell reconstitution. Using CD38/HLA-DR expression on CD8 T cells measured in 2 large studies, we determined associations between TLLV and immune activation levels before, during, and after TLLV. We found that TLLV does not significantly change CD8 T-cell activation and that higher CD8 T-cell activation during viral suppression <50 copies per milliliter is associated with a modest increase in the risk of a subsequent TLLV.",

keywords = "CD8, activation, blip, immune, low level, viremia",

author = "Babafemi Taiwo and Hunt, {Peter W.} and Gandhi, {Rajesh T.} and Andrew Ellingson and Matthew McKenna and Jacobson, {Jeffrey M.} and Barbara Gripshover and Bosch, {Ronald J.}",

year = "2013",

month = may,

day = "1",

doi = "10.1097/QAI.0b013e3182895af4",

language = "English (US)",

volume = "63",

pages = "101--104",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Wolters Kluwer Health",

number = "1",

}

TY - JOUR

T1 - CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy

AU - Taiwo, Babafemi

AU - Hunt, Peter W.

AU - Gandhi, Rajesh T.

AU - Ellingson, Andrew

AU - McKenna, Matthew

AU - Jacobson, Jeffrey M.

AU - Gripshover, Barbara

AU - Bosch, Ronald J.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Transient low-level viremia (TLLV) of 50-400 HIV RNA copies per milliliter is common during antiretroviral therapy, but its pathogenesis, consequences, and optimal management are unclear. Heightened immune activation is associated with detrimental outcomes, including impaired CD4 T-cell reconstitution. Using CD38/HLA-DR expression on CD8 T cells measured in 2 large studies, we determined associations between TLLV and immune activation levels before, during, and after TLLV. We found that TLLV does not significantly change CD8 T-cell activation and that higher CD8 T-cell activation during viral suppression <50 copies per milliliter is associated with a modest increase in the risk of a subsequent TLLV.

AB - Transient low-level viremia (TLLV) of 50-400 HIV RNA copies per milliliter is common during antiretroviral therapy, but its pathogenesis, consequences, and optimal management are unclear. Heightened immune activation is associated with detrimental outcomes, including impaired CD4 T-cell reconstitution. Using CD38/HLA-DR expression on CD8 T cells measured in 2 large studies, we determined associations between TLLV and immune activation levels before, during, and after TLLV. We found that TLLV does not significantly change CD8 T-cell activation and that higher CD8 T-cell activation during viral suppression <50 copies per milliliter is associated with a modest increase in the risk of a subsequent TLLV.

KW - CD8

KW - activation

KW - blip

KW - immune

KW - low level

KW - viremia

UR - http://www.scopus.com/inward/record.url?scp=84876286480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876286480&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e3182895af4

DO - 10.1097/QAI.0b013e3182895af4

M3 - Article

C2 - 23392463

AN - SCOPUS:84876286480

SN - 1525-4135

VL - 63

SP - 101

EP - 104

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - 1

ER -

CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this